Chemotherapy-related bilateral @entity1909 associated with XXXX : reappraisal of epidemiological, clinical, and pathological features.

@entity1 @entity632 @entity2117 @entity203 @entity1544 @entity1909
BACKGROUND: A characteristic @entity203 related to the use of cytostatic chemotherapeutic drugs has been described in the literature. This condition appears to be characterized by an @entity203 , primarily affecting the intertriginous areas bilaterally, together with @entity1544 as the main histologic feature. OBJECTIVE: We sought to establish the epidemiologic, clinical, and histologic characteristics of this poorly defined chemotherapy drug-related @entity203 . METHODS: Retrospective data were collected from 21 consecutive @entity1 with this clinical and histopathologic pattern who attended an oncology center between January 1999 and September 2009. Two skin biopsy specimens were obtained from all @entity1 , with the first being taken within 24 hours of onset, and the second 72 to 96 hours after onset. RESULTS: The @entity1 analyzed were predominantly female (72%), with a mean age of 52 years (range 10-69 years). The lesions presented clinically as bilateral erythematous plaques affecting both axillae (95%), groin (88%), and side aspects of the neck (48%). The main histologic feature in all cases was @entity1544 , characterized by the transformation of the eccrine cuboidal epithelium into two or more layers of squamous cells with intercellular bridges. The onset of the @entity203 appeared within 30 days (range 2-30 days) after the initiation of the cytostatic agent infusion. The lesions resolved with desquamation and @entity2117 . The same cutaneous pattern recurred in up to 50% of @entity1 in whom the oncologist reintroduced the cytostatic treatment. LIMITATIONS: Small sample size was a limitation. CONCLUSIONS: We suggest the term "chemotherapy-related bilateral @entity1909 associated with @entity1544 " to describe this distinctive entity, which is primarily associated with pegylated liposomal @entity632 infusions and chemotherapeutic regimens used in autologous bone-marrow transplantation.
